Cargando…

Identifying High-Risk Tumors within AJCC Stage IB–III Melanomas Using a Seven-Marker Immunohistochemical Signature

SIMPLE SUMMARY: Immunotherapy and targeted therapy are widely accepted for stage III and IV melanoma patients. Clinical investigation of adjuvant therapy in stage II melanoma has already started. Therefore, methods for relapse prediction in lower stage melanoma patients apart from sentinel node biop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reschke, Robin, Gussek, Philipp, Ziemer, Mirjana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229951/ https://www.ncbi.nlm.nih.gov/pubmed/34200680 http://dx.doi.org/10.3390/cancers13122902

Ejemplares similares

Analytical Validation of an Immunohistochemical 7-Biomarker Prognostic Assay (immunoprint(®)) for Early-Stage Cutaneous Melanoma in Archival Tissue of Patients with AJCC v8 T2–T3 Disease
por: Ziemer, Mirjana, et al.
Publicado: (2023)

Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy
por: Reschke, Robin, et al.
Publicado: (2021)

Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients
por: Mactier, Swetlana, et al.
Publicado: (2014)

Risk Stratification and Clinical Characteristics of Patients with Late Recurrence of Melanoma (>10 Years)
por: Reschke, Robin, et al.
Publicado: (2022)

A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden
por: Isaksson, Karolin, et al.
Publicado: (2019)

Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients
por: Kaufman, Kimberley L., et al.
Publicado: (2014)

Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma
por: Kruijff, S., et al.
Publicado: (2011)

Effective Extracorporeal Photopheresis of Patients with Transplantation Induced Acute Intestinal GvHD and Bronchiolitis Obliterans Syndrome
por: Reschke, Robin, et al.
Publicado: (2022)

Early outcome of a 31‐gene expression profile test in 86 AJCC stage IB‐II melanoma patients. A prospective multicentre cohort study
por: Podlipnik, S., et al.
Publicado: (2019)

Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage
por: Teterycz, Pawel, et al.
Publicado: (2019)

Stratification of Patients With Stage IB NSCLC Based on the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual
por: Wu, Lei-Lei, et al.
Publicado: (2020)

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV)
por: Lotem, M, et al.
Publicado: (2002)

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8(TH) EDITION STAGE III MELANOMA PATIENTS
por: Haydu, Lauren, et al.
Publicado: (2019)

S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients
por: Deckers, Eric A., et al.
Publicado: (2019)

AJCC cancer staging manual
Publicado: (1998)

Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the Classification of Thin Cutaneous Melanomas
por: Chu, Vicki H., et al.
Publicado: (2013)

Dermoscopic characteristics of melanoma according to the criteria „ulceration“ and „mitotic rate“ of the AJCC 2009 staging system for melanoma
por: Deinlein, Teresa, et al.
Publicado: (2017)

A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update
por: Biswas, S, et al.
Publicado: (2008)

Immunohistochemical markers and the clinical course of adenosarcoma: a series of seven cases
por: Omi, Makiko, et al.
Publicado: (2020)

Survival analysis following resection of AJCC stage III gallbladder carcinoma based on different combinations of T and N stages
por: Hwang, Kyoung-Yeon, et al.
Publicado: (2015)

Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I–II early‐stage melanoma
por: Ortega‐Martínez, Idoia, et al.
Publicado: (2016)

PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma
por: Glutsch, Valerie, et al.
Publicado: (2022)

AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN
por: Fan, Zhiyao, et al.
Publicado: (2019)

Concordance and Reproducibility of Melanoma Staging According to the 7th vs 8th Edition of the AJCC Cancer Staging Manual
por: Elmore, Joann G., et al.
Publicado: (2018)

Utility of PET-CT in non-small cell lung cancer clinical stage IB-IIA according to AJCC 8th edition staging system: an alternative to invasive mediastinal staging?
por: Buero, Agustin, et al.
Publicado: (2021)

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III
por: Wang, Haiyong, et al.
Publicado: (2017)

Retinoblastoma Survival Following Primary Enucleation by AJCC Staging
por: Zhao, Junyang, et al.
Publicado: (2021)

Discriminatory Ability and Clinical Utility of the AJCC7 and AJCC8 Staging Systems for Breast Cancer in a Middle-Income Setting
por: Song, Chin-Vern, et al.
Publicado: (2023)

Prognostic Value of an Immunohistochemical Signature in Patients With Head and Neck Mucosal Melanoma
por: Xu, Qing-Qing, et al.
Publicado: (2021)

The IGCA staging system is more accurate than AJCC7 system in stratifying survival of patients with gastric cancer in stage III
por: Shu, Ping, et al.
Publicado: (2017)

Aberrant Expression of Immunohistochemical Markers in Malignant Melanoma: A Review
por: Saliba, Elie, et al.
Publicado: (2021)

Novel Prognostic Immunohistochemical Markers in Uveal Melanoma-Literature Review
por: Gajdzis, Malgorzata, et al.
Publicado: (2021)

Comparative study between two different staging systems (AJCC TNM VS BALLANTYNE’S) for mucosal melanomas of the Head & Neck
por: Luna-Ortiz, Kuauhyama, et al.
Publicado: (2016)

A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma
por: Hynes, Matthew C., et al.
Publicado: (2022)

Prognostic stratification of patients with AJCC 2018 pN1 disease in stage III oral squamous cell carcinoma
por: Tsai, Ming-Hsien, et al.
Publicado: (2022)

Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma
por: Cheng, Chih H, et al.
Publicado: (2011)

Markers of Prognosis for Early Stage Cervical Cancer Patients (Stage IB1, IB2) Undergoing Surgical Treatment
por: Xu, Chen, et al.
Publicado: (2021)

Posterior uveal melanoma incidence and survival by AJCC tumour size in a 70‐year nationwide cohort
por: Smidt‐Nielsen, Isabel, et al.
Publicado: (2021)

Prognostic value of systemic inflammatory markers for oral cancer patients based on the 8th edition of AJCC staging system
por: Lee, Sanghoon, et al.
Publicado: (2020)

Evaluation of 7th Edition of AJCC Staging System for Nasopharyngeal Carcinoma
por: Ren, YuFeng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_osodmkrnp06dk0eqgd86qsmdqk